Insulin Pen Market: Analysis Focusing on Top Key Players | Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Medtronic plc, B. Braun Holding GmbH & Co. KG, Owen Mumford Ltd., YpsoMed AG

Global Insulin Pen Market Analysis and Forecast 2019-2028

Market Introduction

The global insulin pen market is expected to witness a considerable growth rate of around 7.3% during the forecast period 2022 to 2028. People diagnosed with type 1 diabetes have to inject insulin on the regular basis. The increasing patient pool of type 1 diabetes is a major factor driving the demand for insulin pens globally.

Download PDF Sample of Insulin Pen Market report @ https://www.themarketinsights.com/request-sample/265150

In addition, continuous technological advancements, like the use of smartphones and the internet with insulin pen offerings are expected to spur the growth of insulin pens in the forthcoming years. The needles on a reusable pen should be replaced periodically. Reusable pens are expected to gain significant traction, mainly driven by a growing base of environment and cost-conscious consumers.

Market Segmentation:

The global insulin pen market is segmented into type, product type, diabetes type, distribution channel, end-user, and region. Based on Type, the market is divided into Conventional Insulin Pen and Smart Insulin Pen. On the basis of Product Type, the market is divided into Reusable Pen and Disposable Pen. Based on diabetes type, the market is divided into Diabetes Type 1 and Diabetes Type 2. On the basis of the Distribution Channel, the market is segmented into Hospital Pharmacies, Conventional Retail Pharmacies, and Online Pharmacies. Based on End Users, the market is divided into Hospitals, Clinics, and Homecare Settings.

To Check Discount @ https://www.themarketinsights.com/check-discount/265150

Based on region, the market is divided into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, and Middle East & Africa. Further, North America is divided into US and Canada. Latin America is further segmented on the basis of Brazil, Mexico, and the Rest of Latin America. Western Europe is further segmented into Germany, the UK, France, Spain, Italy, Benelux, Nordic, and the rest of western Europe. Eastern Europe is segmented into Russia, Poland, and the rest of Eastern Europe. Based on the Asia Pacific, the market is further segmented into China, India, Japan, South Korea, Australia, ASEAN (Indonesia, Vietnam, Malaysia, etc.) countries, and the rest of Asia Pacific. Lastly, on the basis of the Middle East & Africa market is segmented into GCC Countries, South Africa, Turkey, and the rest of the Middle East & Africa.

Market structure and competitive landscape:

The global insulin pen market is fragmented in nature, some of the prominent players that contribute significantly to the market growth include Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Medtronic plc, B. Braun Holding GmbH & Co. KG, Owen Mumford Ltd., YpsoMed AG, Biocon Limited, Terumo Medical Corporation, among others.

Product Launches, Mergers & Acquisitions, joint ventures, and R&D activities are key strategies adopted by the players in the global insulin pen market. These companies adopt numerous approaches to strengthen their market share and gain a competitive edge over other competitors in the market.

Report Customization available as per requirements @ https://www.themarketinsights.com/request-customization/265150

Some of the key developments in the global insulin pen market include,

1. In March 2022, Novo Nordisk A/S launched the smart insulin pen NovoPen 6 and NovoPen Echo Plus in the UK market. By the use of this, people can monitor and record dosing information on their smartphones. These pens can record the amount of insulin injected via a near-field communication mobile application which can be reviewed by patent and healthcare professionals when required.

2. In November 2021, Biocon and Viatris launched an interchangeable insulin biosimilar named Semglee which is a substitute for Sanofi's diabetes drug Lantus. As per the company, the unbranded version of the biosimilar is 65% economical as compared to Sanofi's Lantus.

Partial Table of Content:

Chapter One: Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation

Chapter Two: Assumptions and Acronyms

Chapter Three: Executive Summary

3.1. Global Market in2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends

Chapter Four: Research Methodology

Contact us:

Jessica Joyal
+16146022897
Email: sales@themarketinsights.com
Visit our website: www.themarketinsights.com

About:

Delivering foresights along with statistical analysis of the operational business industry impacts has been our foremost priority. With the constant developments in the research & development industry, we have always challenged the conventional research methodologies and discovered new research tactics to evolve the growing B2B requirements.

This release was published on openPR.